# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

### FORM 8-K/A

### CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 4, 2015

Bacterin Internat	tional Holdings, Inc.
(Exact Name of Registral	nt as Specified in Its Charter)
De	laware
(State or Other Jurison	diction of Incorporation)
001-34951	20-5313323
(Commission File Number)	(IRS Employer Identification No.)
600 Cruiser Lane Belgrade, Montana	59714
(Address of Principal Executive Offices)	(Zip Code)
	388-0480 Jumber, Including Area Code)
(Former Name or Former Addr	ress, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simult provisions (see General Instruction A.2. below):	aneously satisfy the filing obligation of the registrant under any of the following
$\square$ Written communications pursuant to Rule 425 under the Securities Act (17)	7 CFR 230.425)
$\square$ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 C	FR 240.14a-12)
$\square$ Pre-commencement communications pursuant to Rule 14d-2(b) under the	Exchange Act (17 CFR 240.14d-2(b))
$\square$ Pre-commencement communications pursuant to Rule 13e-4(c) under the l	Exchange Act (17 CFR 240.13e-4(c))

#### Item 7.01 Regulation FD Disclosure.

The Company issued a correction and replacement press release entitled "Bacterin Sets Annual Meeting and Record Dates" which is attached as Exhibit 99.1 and incorporated herein.

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

### Item 9.01. Financial Statements and Exhibits.

#### (d) Exhibits.

Exhibit No	Description
99.1	Corrected Press Release of Bacterin International Holdings, Inc. dated May 15, 2015 entitled "Bacterin Sets Annual Meeting and Record Dates"

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 15, 2015 BACTERIN INTERNATIONAL HOLDINGS, INC.

By: /s/ John Gandolfo

Name: John Gandolfo
Title: Chief Financial Officer

## EXHIBIT INDEX

Corrected Press Release of Bacterin International Holdings, Inc. dated May 15, 2015 entitled "Bacterin Sets Annual Meeting and Record Dates"

99.1



# CORRECTING AND REPLACING Bacterin Sets Annual Meeting and Record Dates

BELGRADE, Mont.—(BUSINESS WIRE) — May 15, 2015 — Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary bone graft material, has established a record date for its 2015 annual meeting of stockholders.

Bacterin stockholders of record at the close of business on May 15, 2015 will be entitled to notice of the annual meeting and to vote upon matters considered at the meeting. The annual meeting is scheduled to be held at the Hilton Garden Inn, Denver Tech Center, 7675 E. Union Avenue, Denver, CO 80237 at 8:00 a.m. on June 24, 2015.

Bacterin will make available to all stockholders of record important information about the meeting and the matters to be considered. Stockholders are urged to review that information when it becomes available.

#### **About Bacterin International Holdings**

Bacterin International Holdings, Inc. (OTCQX: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to promote bone growth, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

For further information, please visit www.bacterin.com.



#### **Important Cautions Regarding Forward-looking Statements**

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of the Company's sales force to achieve expected results, the Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage cash flow; the Company's ability to obtain shareholder approval of financing transactions; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the Company's ability to successfully conclude government investigations; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Investor Contact:
COCKRELL GROUP
Rich Cockrell
877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com

Page 2